生物活性 | |||
---|---|---|---|
描述 | Plecanatide is an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, it is approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02387359 | Irritable Bowel Syndrome Chara... 展开 >>cterized by Constipation 收起 << | Phase 3 | Completed | - | - |
NCT01722318 | Irritable Bowel Syndrome Chara... 展开 >>cterized by Constipation 收起 << | Phase 2 | Completed | - | - |
NCT02493452 | Irritable Bowel Syndrome Chara... 展开 >>cterized by Constipation 收起 << | Phase 3 | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
0.59mL 0.12mL 0.06mL |
2.97mL 0.59mL 0.30mL |
5.95mL 1.19mL 0.59mL |
参考文献 |
---|